Rhumbline Advisers Aspira Women'S Health Inc. Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.4 - $1.09 $26,840 - $73,139	-67,100 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$0.88 - $1.81 $70 - $144	-80 Reduced 0.12%	67,100 $70,000
Q4 2021 Feb 10, 2022	SELL	$1.63 - $3.43 $1,189 - $2,503	-730 Reduced 1.07%	67,180 $119,000
Q3 2021 Nov 12, 2021	BUY	$3.19 - $5.48 $7,423 - $12,751	2,327 Added 3.55%	67,910 $221,000
Q2 2021 Aug 05, 2021	SELL	$4.78 - $6.84 $44,057 - $63,044	-9,217 Reduced 12.32%	65,583 $369,000
Q1 2021 May 06, 2021	SELL	$5.9 - $9.13 $2,047 - $3,168	-347 Reduced 0.46%	74,800 $505,000
Q4 2020 Feb 10, 2021	BUY	$3.0 - $6.71 $44,346 - $99,187	14,782 Added 24.49%	75,147 $504,000
Q3 2020 Nov 12, 2020	BUY	$2.54 - $4.56 $30,421 - $54,615	11,977 Added 24.75%	60,365 $186,000
Q2 2020 Aug 13, 2020	BUY	$0.78 - $5.25 $37,742 - $254,037	48,388 New	48,388 $186,000

431K

Ticker AWH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 124,296,000
Market Cap $123M
Description
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gyneco...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.